- ICH GCP
- US Clinical Trials Registry
- Clinical Trial NCT01432262
13-valent Pneumococcal Conjugate Vaccine Study in Adults => 50 Years of Age in Mexico
January 18, 2013 updated by: Pfizer
A Phase 3, Open Label, Single Arm, Multicenter, Trial to Assess The Safety, Tolerability And Immunogenicity Of 13-Valent Pneumococcal Conjugate Vaccine In Healthy Adults Aged => 50 Years of Age Who Are Naive To 23-Valent Pneumococcal Polysaccharide Vaccine in Mexico.
The purpose of this study will be to assess the safety, tolerability, and immunogenicity of 13-Valent Pneumococcal Conjugate Vaccine (13vPnC) when given to healthy adults older than 50 years of age who haven't received 23-valent pneumococcal polysaccharide vaccine in Mexico.
Study Overview
Status
Completed
Conditions
Intervention / Treatment
Study Type
Interventional
Enrollment (Actual)
324
Phase
- Phase 3
Contacts and Locations
This section provides the contact details for those conducting the study, and information on where this study is being conducted.
Study Locations
-
-
-
Durango, Mexico, 34000
- Hospital General de Durango
-
-
D.f.
-
Mexico, D.f., Mexico, 06700
- Instituto Mexicano de Investigación Clínica, S.A. de C.V
-
-
DF
-
Mexico, DF, Mexico, 14000
- Instituto Nacional de Ciencias Medicas y Nutricion Salvador Zubiran
-
-
Michoacan
-
Morelia, Michoacan, Mexico, CP 58070
- Star Medica
-
-
Participation Criteria
Researchers look for people who fit a certain description, called eligibility criteria. Some examples of these criteria are a person's general health condition or prior treatments.
Eligibility Criteria
Ages Eligible for Study
50 years and older (Adult, Older Adult)
Accepts Healthy Volunteers
Yes
Genders Eligible for Study
All
Description
Inclusion Criteria:
- Male or female older than 50 years of age
- Eligibility must be determined by medical history, physical exam and clinical judgment
- Able to complete an electronic diary
- Available for duration of study
- Negative pregnancy test for subjects in group 2 age 50 to 64 years
- Practice abstinence or use reliable birth control if age is 50 to 64 years
Exclusion Criteria:
- History of allergic reaction to any vaccine
- Previous vaccination with licensed or experimental pneumococcal vaccine
- S. pneumonia infection within past 5 years before investigational product administration
- Known or suspected immunodeficiency or received treatment including cytotoxic agents or systemic corticosteroids, serious chronic disorder such as malignancy cancer
- Receipt of plasma products or immunoglobulins within 60 days
- Bleeding conditions or diathesis
- Receipt of investigational product within 28 days before study entry
- Other severe acute or chronic medical or psychiatric condition
Study Plan
This section provides details of the study plan, including how the study is designed and what the study is measuring.
How is the study designed?
Design Details
- Primary Purpose: Prevention
- Allocation: Non-Randomized
- Interventional Model: Parallel Assignment
- Masking: None (Open Label)
Arms and Interventions
Participant Group / Arm |
Intervention / Treatment |
---|---|
Experimental: Group 1
=> 65 years of age
|
Single dose of 0.5 ml of 13vPnC administered in deltoid muscle of arm at visit 1 (day 1)
Other Names:
|
Experimental: Group 2
50 to 64 years of age
|
Single dose of 0.5 ml of 13vPnC administered in deltoid muscle of arm at visit 1 (day 1)
Other Names:
|
What is the study measuring?
Primary Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
---|---|---|
Serotype-Specific Pneumococcal Opsonophagocytic Activity (OPA) Geometric Mean Titers (GMTs) 1 Month After Vaccination
Time Frame: One month (28 to 42 days) after vaccination
|
Serotype-specific OPA GMTs for the 13 pneumococcal serotypes (1, 3, 4, 5, 6A, 6B, 7F, 9V, 14, 18C, 19A, 19F, and 23F) were determined in the blood samples of all the participants using a quantitative functional OPA assay.
Confidence intervals (CIs) for GMT are back transformations of a CI based on the Student t distribution for the mean logarithm of the titers.
Individual OPA assay values below the assay LLOQ (lower limit of quantification) were set at a titer of 0.5*limit of detection (LOD [8]) = (titer of 4) for the purpose of calculating the OPA GMT.
|
One month (28 to 42 days) after vaccination
|
Percentage of Participants Reporting Pre-Specified Local Reactions Within 14 Days After Vaccination
Time Frame: Within 14 days after vaccination
|
Local reactions reported using an electronic diary.
Redness and Swelling scaled as Any (redness present or swelling present), Mild (2.5 to 5.0 centimeters [cm]), Moderate (5.1 to 10.0 cm), Severe (>10 cm).
Pain at injection site scaled as Any (pain present), Mild (does not interfere with activity), Moderate (interferes with activity), Severe (prevents daily activity).
|
Within 14 days after vaccination
|
Percentage of Participants Reporting Pre-Specified Systemic Events Within 14 Days After Vaccination
Time Frame: Within 14 days after vaccination
|
Systemic events reported using electronic diary.
Fever-Any:>=38 degrees Celsius (C), Mild (M):>=38 to <38.5 degrees C, Moderate(Mod):>=38.5 to <39 degrees C, Severe (S):>=39 to <=40 degrees C, Potentially life threatening:>40 degrees C. Headache, fatigue, muscle pain, joint pain- Any: present, M:did not interfere with activity, Mod:some interference, S:activity prevented.
Vomiting- Any:present, M:1-2 times/day (d), Mod:>2/d, S:required intravenous hydration.
Diarrhoea- Any:present, M:2-3 loose stools/d, Mod:4-5/d, S:>=6/d.
All reports of fever >40 degrees C were confirmed as data entry errors.
|
Within 14 days after vaccination
|
Percentage of Participants With Treatment-Emergent Adverse Events (AEs) or Serious Adverse Events (SAEs)
Time Frame: Baseline up to 1 Month (28 to 42 days) after vaccination
|
An AE was any untoward medical occurrence in a participant who received vaccine without regard to possibility of causal relationship.
An SAE was an AE resulting in any of the following outcomes or deemed significant for any other reason: death; initial/prolonged inpatient hospitalization; life-threatening experience (immediate risk of dying); persistent or significant disability/incapacity; congenital anomaly.
Treatment-emergent are events between vaccination and up to 1 month (28 to 42 days) after vaccination that were absent before treatment or that worsened relative to pre-treatment state.
|
Baseline up to 1 Month (28 to 42 days) after vaccination
|
Secondary Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
---|---|---|
Percentage of Participants Achieving Serotype-Specific Opsonophagocytic Activity (OPA) Titer With at Least Lower Limit of Quantification (LLOQ) 1 Month After Vaccination
Time Frame: One month (28 to 42 days) after vaccination
|
Percentage of participants achieving OPA GMTs with at least LLOQ for 13 pneumococcal serotypes (1, 3, 4, 5, 6A, 6B, 7F, 9V, 14, 18C, 19A, 19F and 23F) determined in blood samples of all participants using microcolony OPA assay.
Exact 2-sided CI based on observed proportion of participants.
LLOQ for each serotype: 1=1:18, 3=1:12, 4=1:21, 5=1:29, 6A=1:37, 6B=1:43, 7F=1:210, 9V=1:345, 14=1:35, 18C=1:31, 19A=1:18, 19F=1:48, 23F=1:13.
|
One month (28 to 42 days) after vaccination
|
Serotype-Specific Pneumococcal Opsonophagocytic Activity (OPA) Geometric Mean Fold Rise (GMFR) From Pre-Vaccination to 1 Month Post-Vaccination
Time Frame: Pre-vaccination to 1 month (28 to 42 days) after vaccination
|
Geometric mean fold rises (GMFRs) for the 13 pneumococcal serotypes (1, 3, 4, 5, 6A, 6B, 7F, 9V, 14, 18C, 19A, 19F, and 23F) from pre-vaccination to 1 month post-vaccination were computed using the logarithmically transformed assay results.
CIs for GMFR are back transformations of a CI based on the Student t distribution for the mean logarithm of the titers.
|
Pre-vaccination to 1 month (28 to 42 days) after vaccination
|
Collaborators and Investigators
This is where you will find people and organizations involved with this study.
Sponsor
Publications and helpful links
The person responsible for entering information about the study voluntarily provides these publications. These may be about anything related to the study.
Study record dates
These dates track the progress of study record and summary results submissions to ClinicalTrials.gov. Study records and reported results are reviewed by the National Library of Medicine (NLM) to make sure they meet specific quality control standards before being posted on the public website.
Study Major Dates
Study Start
July 1, 2011
Primary Completion (Actual)
December 1, 2011
Study Completion (Actual)
December 1, 2011
Study Registration Dates
First Submitted
June 22, 2011
First Submitted That Met QC Criteria
September 8, 2011
First Posted (Estimate)
September 12, 2011
Study Record Updates
Last Update Posted (Estimate)
January 25, 2013
Last Update Submitted That Met QC Criteria
January 18, 2013
Last Verified
January 1, 2013
More Information
Terms related to this study
Keywords
Additional Relevant MeSH Terms
Other Study ID Numbers
- B1851048
- 6115A1-3020
This information was retrieved directly from the website clinicaltrials.gov without any changes. If you have any requests to change, remove or update your study details, please contact register@clinicaltrials.gov. As soon as a change is implemented on clinicaltrials.gov, this will be updated automatically on our website as well.
Clinical Trials on Pneumococcal Infections
-
Johns Hopkins Bloomberg School of Public HealthPfizer; National Institutes of Health (NIH); Centers for Disease Control and...CompletedInvasive Pneumococcal Disease | Pneumococcal Nasopharyngeal ColonizationUnited States
-
Institut National de la Santé Et de la Recherche...CompletedPneumococcal DiseasesFrance
-
Wyeth is now a wholly owned subsidiary of PfizerPfizerCompletedInvasive Pneumococcal DiseaseIceland
-
GlaxoSmithKlineCompletedProphylactic Pneumococcal DiseasesBelgium
-
Centers for Disease Control and PreventionKaiser PermanenteCompletedPneumococcal Disease PreventionUnited States
-
PfizerCompletedPneumococcal Disease | 13-valent Pneumococcal VaccineUnited States
-
Walvax Biotechnology Co., Ltd.Enrolling by invitationPneumococcal Disease, InvasiveIndonesia
-
PfizerCompletedInvasive Pneumococcal DiseaseSpain
-
PfizerKaiser PermanenteCompletedInvasive Pneumococcal DiseaseUnited States
-
PfizerCompletedPneumococcal DiseasesTurkey
Clinical Trials on vaccine-13vPnC
-
PfizerCompletedPneumococcal Conjugate VaccineFrance, United States, United Kingdom, Lebanon, Italy, Egypt, Saudi Arabia
-
PfizerCompletedPneumococcal Infections | Pneumonia, Pneumococcal | 13-valent Pneumococcal VaccineNetherlands
-
PfizerCompletedPneumococcal InfectionsUnited States
-
PfizerCompletedPneumococcal InfectionsSweden, United States, Germany
-
PfizerCompletedPneumococcal InfectionsJapan
-
PfizerCompleted
-
Wyeth is now a wholly owned subsidiary of PfizerPfizerCompletedInvasive Pneumococcal DiseaseIceland
-
PfizerCompletedHIV Infections | Pneumococcal InfectionsUnited States
-
PfizerCompletedPneumococcal DiseasePhilippines
-
PfizerCompletedPneumococcal Vaccines | Pneumococcal Conjugate VaccineJapan